Market Place
Sourcing Support
All News #Library
Rare Diseases
Travere`s Drug For Rare Kidney Disease Gets Expanded FDA Approval
14 Apr 2026 //
REUTERS
Travere Shares Fall as US FDA Extends Review of Rare Kidney Drug
13 Jan 2026 //
REUTERS
CSL Vifor, Travere Therapeutics Acknowledge New KDIGO Guidelines
26 Sep 2025 //
PR NEWSWIRE
Travere Gets FDA Nod for REMS Modification on filspari
28 Aug 2025 //
BUSINESSWIRE
Travere to Present Filspari Data at Podocyte Conference
11 Jun 2025 //
BUSINESSWIRE
Travere’s sNDA for FILSPARI® in FSGS Accepted by FDA
15 May 2025 //
BUSINESSWIRE
Travere Therapeutics to Report Third Quarter 2024 Financial Results
21 Oct 2024 //
GLOBENEWSWIRE
Travere pauses trial enrollment over manufacturing scale-up woes
27 Sep 2024 //
FIERCE PHARMA
Travere To Present At Cantor Healthcare Conference
10 Sep 2024 //
GLOBENEWSWIRE
Travere`s Filspari misses the mark in rare kidney disease trial
22 Sep 2023 //
FIERCE PHARMA
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.